Medincell Drops 8.56% in Session Despite Overbought RSI
Medincell falls by 8.56% to 26.70 euros on Monday, January 26, 2026, after testing its resistance at 29.20 euros, amid a high RSI at 78 indicating an overbought zone. The correction occurs despite favorable analyst recommendations and the anticipated approval of Olanzapine LAI scheduled for October 2026.
Session Overview
The MEDINCELL stock opened lower this Monday, January 26, recording a decline of 8.56% to settle at 26.70 euros from 29.20 euros the previous day. This correction followed after the stock tested its resistance level at 29.20 euros, now marking a short-term technical ceiling. The identified support at 23.90 euros provides a potential base should the downward movement extend. The traded volumes account for 0.4% of the capital, indicating a moderate level that suggests a technical consolidation rather than a panic movement. The Relative Strength Index stands at 78 points, a level signaling a pronounced overbought zone. This high RSI positioning reflects an excessive bullish tension accumulated in previous sessions, justifying a technical breathing phase. The stock is trading above its 50-day moving average set at 27.13 euros, but the proximity of this threshold suggests an immediate vigilance zone. In the longer term, the price remains well above the 200-day moving average at 21.75 euros, confirming a positive underlying trend despite recent volatility of 11.96% over a month.
Fundamental Context
The fundamental context of Medincell is buoyed by expectations surrounding the launch of Olanzapine LAI, with regulatory approval anticipated in October 2026 according to analysts. Oddo BHF recently raised its price target from 27 to 34 euros on January 16, while maintaining an outperformance recommendation, highlighting the revenue potential linked to Uzedy and development programs. Jefferies has set a more ambitious target at 50 euros, while TP Icap Midcap has taken a more cautious stance with a target at 32 euros and a downgraded recommendation to hold. These differing assessments reflect uncertainties related to the realization of sales forecasts and regulatory timelines. The MACD histogram at 0.35 confirms a positive short-term momentum, although the day's correction may mark the beginning of a consolidation phase. The Bollinger Bands frame the price between 23.30 euros at the bottom and 29.23 euros at the top, with the stock now moving in the middle part of this range after testing the upper limit. The next annual results for the fiscal year 2025-2026 are expected on June 16, 2026, a milestone that will structure investor expectations on the commercial trajectory of Uzedy and the progress of the development pipeline.
